The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Bevacizumab (Bev) plus chemotherapy for advanced gastroesophageal adenocarcinoma (GC): Combined U.S. experience.
E. C. Smyth
No relevant relationships to disclose
P. C. Enzinger
Consultant or Advisory Role - Genentech
Research Funding - Genentech
J. Li
No relevant relationships to disclose
M. Vincitore
No relevant relationships to disclose
J. Lacy
No relevant relationships to disclose
B. F. El-Rayes
No relevant relationships to disclose
P. L. Kunz
Research Funding - Genentech
J. M. Ford
No relevant relationships to disclose
E. Robinson
No relevant relationships to disclose
D. P. Kelsen
No relevant relationships to disclose
M. A. Shah
No relevant relationships to disclose